{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T04:56:40Z","timestamp":1772945800953,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pfizer Colombia","award":["B0661186"],"award-info":[{"award-number":["B0661186"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00701-0","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T09:46:00Z","timestamp":1769247960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of resources and cost in the management of gastrointestinal hemorrhage caused by oral anticoagulants: a retrospective cohort analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Manuel Enrique","family":"Machado-Duque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Gaviria-Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Valladales-Restrepo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Mauricio","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mesa-Urdinola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Constanza","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia Casta\u00f1o","family":"Gamboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Enrique","family":"Machado-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"8","key":"701_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983\u20138.","journal-title":"Stroke"},{"issue":"2","key":"701_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/14779072.2021.1873766","volume":"19","author":"DA Medina-Morales","year":"2021","unstructured":"Medina-Morales DA, Machado-Duque ME, Gaviria-Mendoza A, et al. Clinical characteristics and stratification of the cerebrovascular accident risk among patients with atrial fibrillation in Colombia, 2011\u20132016. Expert Rev Cardiovasc Ther. 2021;19(2):181\u20137.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"1","key":"701_CR3","first-page":"26","volume":"24","author":"V Mora-Llabata","year":"2017","unstructured":"Mora-Llabata V, Dubois-Marqu\u00e9s D, Rold\u00e1n-Torres I, et al. Prevalencia de fibrilaci\u00f3n auricular y caracter\u00edsticas de La fibrilaci\u00f3n auricular no valvular En La poblaci\u00f3n general. Registro AFINVA Rev Colomb Cardiol. 2017;24(1):26\u201333.","journal-title":"Registro AFINVA Rev Colomb Cardiol"},{"issue":"6","key":"701_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40256-017-0244-1","volume":"17","author":"AM Gilligan","year":"2017","unstructured":"Gilligan AM, Gandhi P, Song X, et al. All-Cause, Stroke-, and Bleed-Specific healthcare costs: comparison among patients with Non-Valvular atrial fibrillation (NVAF) newly treated with Dabigatran or warfarin. Am J Cardiovasc Drugs. 2017;17(6):481\u201392.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"701_CR5","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.ijcard.2013.01.184","volume":"167","author":"TN Nguyen","year":"2013","unstructured":"Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412\u201320.","journal-title":"Int J Cardiol"},{"key":"701_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2019.02.001","volume":"212","author":"ED Peterson","year":"2019","unstructured":"Peterson ED, Ashton V, Chen YW, et al. Comparative effectiveness, safety, and costs of Rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J. 2019;212:113\u20139.","journal-title":"Am Heart J"},{"issue":"8","key":"701_CR7","first-page":"1056","volume":"27","author":"ES Wong","year":"2021","unstructured":"Wong ES, Done N, Zhao M, et al. Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees. J Manag Care Spec Pharm. 2021;27(8):1056\u201366.","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"701_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.7326\/M19-1795","volume":"171","author":"AN Barkun","year":"2019","unstructured":"Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper Gastrointestinal bleeding: guideline recommendations from the international consensus group. Ann Intern Med. 2019;171(11):805\u201322.","journal-title":"Ann Intern Med"},{"issue":"5","key":"701_CR9","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s10557-021-07211-0","volume":"36","author":"R Benamouzig","year":"2022","unstructured":"Benamouzig R, Guenoun M, Deutsch D, et al. Review article: Gastrointestinal bleeding risk with direct oral anticoagulants. Cardiovasc Drugs Ther. 2022;36(5):973\u201389.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"701_CR10","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cgh.2019.05.056","volume":"18","author":"ZC Gu","year":"2020","unstructured":"Gu ZC, Wei AH, Zhang C, et al. Risk of major Gastrointestinal bleeding with new vs conventional oral anticoagulants: A systematic review and Meta-analysis. Clin Gastroenterol Hepatol. 2020;18(4):792\u2013e79961.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"701_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.giec.2011.07.004","volume":"21","author":"C Sostres","year":"2011","unstructured":"Sostres C, Lanas A. Epidemiology and demographics of upper Gastrointestinal bleeding: prevalence, incidence, and mortality. Gastrointest Endosc Clin N Am. 2011;21(4):567\u201381.","journal-title":"Gastrointest Endosc Clin N Am"},{"issue":"5","key":"701_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2217\/fca-2019-0033","volume":"15","author":"SV Ramagopalan","year":"2019","unstructured":"Ramagopalan SV, Samnaliev M, Weir S, et al. Costs of Gastrointestinal bleeding events in atrial fibrillation: a UK clinical practice research datalink study. Future Cardiol. 2019;15(5):367\u201375.","journal-title":"Future Cardiol"},{"key":"701_CR13","unstructured":"Colombia. Banco de la Republica. Tasa Representativa del Mercado (TRM - Peso por d\u00f3lar) Bogot\u00e1, DC.2024. Available from: https:\/\/www.banrep.gov.co\/es\/estadisticas\/trm"},{"key":"701_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejim.2018.11.003","volume":"61","author":"MV Lenti","year":"2019","unstructured":"Lenti MV, Pasina L, Cococcia S, et al. REPOSI Investigators. Mortality rate and risk factors for Gastrointestinal bleeding in elderly patients. Eur J Intern Med. 2019;61:54\u201361.","journal-title":"Eur J Intern Med"},{"key":"701_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/VHRM.S391549","volume":"19","author":"ME Machado-Duque","year":"2023","unstructured":"Machado-Duque ME, Gaviria-Mendoza A, Reyes JM, et al. Clinical Characteristics, patterns of Use, and incidence of adverse events in patients with nonvalvular atrial fibrillation treated with oral anticoagulants in Colombia. Vasc Health Risk Manag. 2023;19:157\u201367.","journal-title":"Vasc Health Risk Manag"},{"issue":"9921","key":"701_CR16","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"issue":"4","key":"701_CR17","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pds.5124","volume":"30","author":"JE Machado-Alba","year":"2021","unstructured":"Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, et al. Use of non-vitamin K antagonist oral anticoagulants in colombia: A descriptive study using a National administrative healthcare database. Pharmacoepidemiol Drug Saf. 2021;30(4):426\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"701_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijcard.2020.06.032","volume":"320","author":"T Akhtar","year":"2020","unstructured":"Akhtar T, Fratti JDC, Mattumpuram J, et al. Factors associated with bleeding events in patients on Rivaroxaban for non-valvular atrial fibrillation: A real-world experience. Int J Cardiol. 2020;320:78\u201382.","journal-title":"Int J Cardiol"},{"issue":"1","key":"701_CR19","doi-asserted-by":"publisher","first-page":"e2021017","DOI":"10.4084\/mjhid.2021.017","volume":"13","author":"F Hanna","year":"2021","unstructured":"Hanna F, Hyppa A, Prakash A, et al. Real-World data on characteristics and management of community patients receiving anticoagulation therapy who presented with acute bleeding to the emergency department at a regional Australian hospital: A prospective observational study. Mediterr J Hematol Infect Dis. 2021;13(1):e2021017.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"701_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3892\/etm.2020.9335","volume":"20","author":"AI Suceveanu","year":"2020","unstructured":"Suceveanu AI, Suceveanu AP, Parepa I, et al. Reducing upper digestive bleeding risk in patients treated with direct oral anticoagulants and concomitant infection with Helicobacter pylori. Exp Ther Med. 2020;20(6):205.","journal-title":"Exp Ther Med"},{"issue":"1","key":"701_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/03007995.2018.1543184","volume":"35","author":"BR Shah","year":"2019","unstructured":"Shah BR, Scholtus E, Rolland C, et al. A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation. Curr Med Res Opin. 2019;35(1):127\u201339.","journal-title":"Curr Med Res Opin"},{"key":"701_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.thromres.2019.07.026","volume":"182","author":"Y Xu","year":"2019","unstructured":"Xu Y, Schulman S, Dowlatshahi D, et al. Bleeding effected by direct oral anticoagulants (BLED-AC) study Group. Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thromb Res. 2019;182:12\u20139.","journal-title":"Thromb Res"},{"issue":"7","key":"701_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jamacardio.2022.1292","volume":"7","author":"B Bikdeli","year":"2022","unstructured":"Bikdeli B, Zahedi Tajrishi F, et al. Efficacy and safety considerations with Dose-Reduced direct oral anticoagulants: A review. JAMA Cardiol. 2022;7(7):776.","journal-title":"JAMA Cardiol"},{"key":"701_CR24","unstructured":"DANE. Departamento Administrativo Nacional de Estad\u00edstica. Producto Interno Bruto (PIB) nacional trimestral. Colombia Bogot\u00e1 D.C2023 [Available from: https:\/\/www.dane.gov.co\/index.php\/estadisticas-por-tema\/cuentas-nacionales\/cuentas-nacionales-trimestrales\/pib-informacion-tecnica"},{"issue":"3","key":"701_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00004836-199106000-00005","volume":"13","author":"JM Richter","year":"1991","unstructured":"Richter JM, Wang TC, Fawaz K, et al. Practice patterns and costs of hospitalization for upper Gastrointestinal hemorrhage. J Clin Gastroenterol. 1991;13(3):268\u201373.","journal-title":"J Clin Gastroenterol"},{"issue":"7","key":"701_CR26","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1111\/j.1572-0241.1999.01215.x","volume":"94","author":"JK Marshall","year":"1999","unstructured":"Marshall JK, Collins SM, Gafni A. Prediction of resource utilization and case cost for acute nonvariceal upper Gastrointestinal hemorrhage at a Canadian community hospital. Am J Gastroenterol. 1999;94(7):1841\u20136.","journal-title":"Am J Gastroenterol"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00701-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00701-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:26:47Z","timestamp":1772893607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-025-00701-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00701-0","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following original publication, affiliation 2 has been updated to correct \u201cInstituci\u00f3n educativa Visi\u00f3n de las Americas\u201d to \u201cInstituci\u00f3n Universitaria Visi\u00f3n de las Am\u00e9ricas\u201d.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Bioethics Committee of the Universidad Tecnol\u00f3gica de Pereira under the \u201cno risk\u201d research category (approval code: 76-241022. Date: October 22, 2021). The ethical principles established by the Declaration of Helsinki were followed. Risk-free investigations that collect data from clinical records do not require informed consent according to Resolution 8430 of 1993 of the Colombian Ministry of Health. According to regulations in Colombia, observational studies conducted on secondary databases do not require informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and consent to participate"}},{"value":"All authors agree to the publication of the manuscript in its final version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Reyes JM, Casta\u00f1o-Gamboa N, Rubio A and Mesa A are employees of Pfizer. Pfizer did not participate in the management or data analysis of the study information. Gaviria-Mendoza A, Machado-Duque M, Valladales-Restrepo L, and Machado-Alba J have developed studies funded by GSK, Pfizer, Biotoscana, Sanofi, Sanofi-Pasteur, Abbot, Tecnoqu\u00edmicas, Bayer, and Novartis. G\u00f3mez D has not conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}